Primetime awarded SBIR Fast-Track grant to develop a novel anti-depressant treatment
GERMANTOWN, Md. - Aug. 13, 2018 - PRLog -- Primetime Life Sciences, LLC, a pharmaceutical company focused on discovery and development of new and smart treatments by using a multi-disciplinary, highly collaborative "bench-to-bedside"
The funds for this Fast Track SBIR grant will be released in two parts. An initial Phase I award of $350,042 is granted in the near term. Phase II of the project would support pre-clinical studies towards IND submission of our lead compound. Together, the Fast-Track SBIR grant has the potential to provide a total of $2.98 million in nondilutive financial resources.
"Receiving a highly competitive SBIR award is a validation of our approach to developing an innovative treatment for depression,"
NOTES TO EDITORS
About Primetime Life Sciences, LLC
Primetime Life Sciences (www.primetimelifesci.com)
Janak Padia, Ph.D.